高级检索
当前位置: 首页 > 详情页

NOP58 induction potentiates chemoresistance of colorectal cancer cells through aerobic glycolysis as evidenced by proteomics analysis

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Collaborat Hebei Med Univ, Coll Forens Med, Innovat Ctr Forens Med Mol Identificat, Hebei Key Lab Forens Med, Shijiazhuang, Hebei, Peoples R China [2]Hebei Med Univ, Hosp 4, Dept Surg 2, Shijiazhuang, Hebei, Peoples R China [3]Hebei Med Univ, Chinese Acad Med Sci, Res Unit Digest Tract Microecosyst Pharmacol & Tox, Shijiazhuang, Hebei, Peoples R China [4]China Pharmaceut Univ, Nanjing, Peoples R China [5]Hebei Med Univ, Inst Basic Med, Dept Pathogen Biol, Shijiazhuang, Peoples R China [6]Hebei Med Univ, Hosp 2, Dept Surg, Shijiazhuang, Hebei, Peoples R China
出处:
ISSN:

关键词: colorectal cancer chemoresistance aerobic glycolysis 5-FU NOP58

摘要:
Introduction: The majority of individuals diagnosed with advanced colorectal cancer (CRC) will ultimately acquire resistance to 5-FU treatment. An increasing amount of evidence indicates that aerobic glycolysis performs a significant function in the progression and resistance of CRC. Nevertheless, the fundamental mechanisms remain to be fully understood.Methods: Proteomic analysis of 5-FU resistant CRC cells was implemented to identify and determine potential difference expression protein.Results: These proteins may exhibit resistance mechanisms that are potentially linked to the process of aerobic glycolysis. Herein, we found that nucleolar protein 58 (NOP58) has been overexpressed within two 5-FU resistant CRC cells, 116-5FuR and Lovo-5FuR. Meanwhile, the glycolysis rate of drug-resistant cancer cells has increased. NOP58 knockdown decreased glycolysis and enhanced the sensitivity of 116-5FuR and Lovo-5FuR cells to 5FU.Conclusion: The proteomic analysis of chemoresistance identifies a new target involved in the cellular adaption to 5-FU and therefore highlights a possible new therapeutic strategy to overcome this resistance.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 药学
JCR分区:
出版当年[2023]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2024]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Collaborat Hebei Med Univ, Coll Forens Med, Innovat Ctr Forens Med Mol Identificat, Hebei Key Lab Forens Med, Shijiazhuang, Hebei, Peoples R China [2]Hebei Med Univ, Hosp 4, Dept Surg 2, Shijiazhuang, Hebei, Peoples R China [3]Hebei Med Univ, Chinese Acad Med Sci, Res Unit Digest Tract Microecosyst Pharmacol & Tox, Shijiazhuang, Hebei, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Collaborat Hebei Med Univ, Coll Forens Med, Innovat Ctr Forens Med Mol Identificat, Hebei Key Lab Forens Med, Shijiazhuang, Hebei, Peoples R China [2]Hebei Med Univ, Hosp 4, Dept Surg 2, Shijiazhuang, Hebei, Peoples R China [3]Hebei Med Univ, Chinese Acad Med Sci, Res Unit Digest Tract Microecosyst Pharmacol & Tox, Shijiazhuang, Hebei, Peoples R China [5]Hebei Med Univ, Inst Basic Med, Dept Pathogen Biol, Shijiazhuang, Peoples R China [6]Hebei Med Univ, Hosp 2, Dept Surg, Shijiazhuang, Hebei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号